MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, KAPA had $2,541K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$2,541K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Proceeds from common stock issued for cash in connection with the closing of the initial public offering
0 -
Proceeds from notes payable - officers
0 0
Payment of deferred offering costs
0 0
Proceeds from the sale and exercise of prefunded warrants
0 3,058
Proceeds from the equity line of credit
3,379 223
Net cash provided by financing activities
3,379 3,281
Debt discount amortization
0 0
Fair value of common shares issued in connection with the conversion of accounts payable
0 -
Fair value of warrants issued in connection with convertible notes payable
0 -
Vendor advances
0 -
Amortization of vendor advances
660 1,298
Fair value of vested restricted stock units
70 153
Prepaid expenses and other current assets
-64 50
Accounts payable and accrued expenses
-274 -316
Net loss
-1,398 -2,684
Amortization of intangible asset
40 80
Net cash used in operating activities
-838 -1,519
Net increase in cash and cash equivalents
2,541 1,762
Cash and cash equivalents at beginning of period
1,272 -
Cash and cash equivalents at end of period
5,575 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Kairos Pharma, LTD. (KAPA)

Kairos Pharma, LTD. (KAPA)